IRIS
CANTINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.599
EU - Europa 549
AS - Asia 399
AF - Africa 63
SA - Sud America 58
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 2.673
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.595
SG - Singapore 132
IT - Italia 126
CN - Cina 122
HK - Hong Kong 106
RU - Federazione Russa 101
IE - Irlanda 90
SE - Svezia 77
BR - Brasile 51
CI - Costa d'Avorio 43
DE - Germania 35
GB - Regno Unito 35
UA - Ucraina 20
MA - Marocco 19
FR - Francia 17
IN - India 16
BE - Belgio 11
FI - Finlandia 11
AR - Argentina 6
JP - Giappone 5
AT - Austria 4
CA - Canada 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
TR - Turchia 4
EU - Europa 3
KR - Corea 3
NL - Olanda 3
RO - Romania 3
UZ - Uzbekistan 3
AU - Australia 2
AZ - Azerbaigian 2
PL - Polonia 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
IL - Israele 1
IQ - Iraq 1
KG - Kirghizistan 1
LT - Lituania 1
PH - Filippine 1
PK - Pakistan 1
VE - Venezuela 1
VN - Vietnam 1
Totale 2.673
Salva come PNG Salva come JPEG
Città #
Chandler 274
Des Moines 241
Hong Kong 106
Ashburn 101
Fairfield 99
Boardman 86
Dublin 85
Singapore 80
New York 71
Ann Arbor 51
Wilmington 45
Abidjan 43
Seattle 40
Woodbridge 39
Jacksonville 33
Cambridge 32
Lawrence 32
Princeton 32
Houston 30
Turin 30
San Mateo 25
San Diego 24
Moscow 20
Pune 15
Beijing 14
Washington 14
Ancona 12
London 12
Munich 12
Brussels 11
Dallas 11
Los Angeles 11
Santa Clara 10
The Dalles 10
Turku 8
Shanghai 7
Guangzhou 6
Redmond 6
Shenzhen 6
Falls Church 5
Tolentino 5
Wuhan 5
Zhengzhou 5
Arnold 4
Nuremberg 4
Qualiano 4
Buffalo 3
Chicago 3
Curitiba 3
Fermignano 3
Kilburn 3
Olomouc 3
Prescot 3
Qingdao 3
Rio de Janeiro 3
Tashkent 3
Wuxi 3
Baku 2
Bauru 2
Bellante 2
Belo Horizonte 2
Brasília 2
Caraguatatuba 2
Caserta 2
Castelraimondo 2
Centro 2
Chongqing 2
Dongguan 2
Fabriano 2
Falkenstein 2
Hefei 2
Helsinki 2
Itapevi 2
Jiaxing 2
Jinan 2
Kagoya 2
Macerata 2
Milan 2
Norwalk 2
Parma 2
Recanati 2
San Francisco 2
Slobozia 2
St Petersburg 2
São Paulo 2
Vienna 2
Warsaw 2
Abelardo Luz 1
Acerra 1
Acton 1
Amandola 1
Amsterdam 1
Ankang 1
Ankara 1
Anyang 1
Athens 1
Atlanta 1
Aversa 1
Baghdad 1
Bagé 1
Totale 1.922
Salva come PNG Salva come JPEG
Nome #
Are liver nested stromal epithelial tumors always low aggressive? 124
Optimal management of resected gastric cancer 118
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 118
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 116
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 111
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 106
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 100
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 94
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 93
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 89
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 87
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 84
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 83
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 77
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 77
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 75
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 73
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 72
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 71
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 71
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 71
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 68
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 68
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 64
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 56
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 55
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 54
Cancer patient perspective in the arena of COVID-19 pandemic 47
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 46
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 46
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 45
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 42
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 42
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 41
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 41
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 37
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 33
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 28
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 22
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 17
Totale 2.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019 0 0 0 0 0 0 0 0 0 0 6 13
2020/2021315 7 13 60 49 26 6 4 20 23 20 51 36
2021/2022281 3 26 5 6 17 34 13 15 50 16 38 58
2022/2023869 54 90 40 70 44 286 0 43 141 8 73 20
2023/2024419 69 10 29 32 49 131 3 8 0 17 6 65
2024/2025780 155 79 38 21 40 53 76 41 165 42 70 0
Totale 2.762